22/06/2026 Exelixis’ STELLAR-303 trial showed OS benefit in ITT, non‑significant trend in NLM in mCRC; FDA decision due Dec 2026 SystImmune secures world’s first bispecific ADC approval with iza-bren in China CARsgen secures NMPA approval for satri-cel, the world’s first CAR-T therapy in solid tumors, targeting Claudin18.2-positive advanced gastric cancer Sigvotatug vedotin in metastatic non-squamous NSCLC missed OS in the overall population but showed promising efficacy in s

24/11/2025 Avenzo Therapeutics' AVZO-103 received the FDA fast track designation for metastatic urothelial cancer (Ref) The US FDA granted the fast track desingation to Avenzo Therapeutics' AVZO-103 (Nectin4/TROP2 bispecific antibody-drug conjugate) for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received enfortumab vedotin. Mohammad Hirmand, M.D., Co-founder and Chief Medical Officer, Avenzo Therapeutics: “Receivi

08/07/2025 Adagene and ConjugateBio sign a partnership agreement to develop novel ADC (Ref) Adagene announced a partnership with ConjugateBio to provide a proprietary antibody for use in partner companies’ bispecific ADC development programs Under the terms of the agreement, Adagene will receive an undisclosed upfront payment, as well as milestone and royalty payments Adagene will provide an internally developed antibody for novel bispecific ADC development Adagene retains al